Tags

Type your tag names separated by a space and hit enter

Postvaccination infections among staff of a tertiary care hospital after vaccination with severe acute respiratory syndrome coronavirus 2 vector and mRNA-based vaccines.
Clin Microbiol Infect. 2022 Apr; 28(4):596-601.CM

Abstract

OBJECTIVES

The identification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen or RNA in respiratory specimens ≥14 days after administration of all recommended doses of authorized coronavirus disease 2019 (COVID-19) vaccines is defined as breakthrough infection. In the present investigation, mRNA and vector-based SARS-CoV-2 vaccines were analysed with respect to postvaccination infections in vaccinated hospital employees.

METHODS

A total of 8553 staff members were vaccinated with BNT162b2 (47%) or ChAdOx1-S (53%) between January and May 2021. In a retrospective observational cohort study, incidence of SARS-CoV-2 postvaccination infections was analysed in relation to demographic data, viral load, virus variants, vaccine brand and vaccination status at time of positive PCR test (fully vaccinated: ≥14 days since second dose; partially vaccinated: >21 days since first, but <14 days after second dose; insufficiently vaccinated: <22 days since first dose).

RESULTS

Within the follow-up period, ending on 31 July 2021, person-time at risk-adjusted monthly rates for SARS-CoV-2 postvaccination infections were 0.18% (BNT162b2) and 0.57% (ChAdOx1-S) for insufficiently vaccinated, 0.34% (BNT162b2) and 0.32% (ChAdOx1-S) for partially vaccinated and 0.06% (BNT162b2) and 0.04% (ChAdOx1-S) for fully vaccinated participants. The two vaccine types did not differ with respect to hazard ratios for any of the respective postvaccination infection types. No cases of COVID-19-related hospitalizations or deaths were reported. Genotyping of positive PCR specimens revealed 42 variants of concern: B.1.1.7 (Alpha variant; n = 34); B.1.351 (Beta variant; n = 2), B.1.617.2 (Delta variant; n = 6).

CONCLUSIONS

BNT162b2 and ChAdOx1-S are both effective in preventing breakthrough infections; however, it seems important, that all recommended vaccine doses are administered.

Authors+Show Affiliations

Department of Medicine II, Division of Angiology, Medical University of Vienna, Vienna, Austria. Electronic address: sophie.brunner-ziegler@meduniwien.ac.at.Department of Hospital Epidemiology and Infection Control, Medical University of Vienna, Vienna, Austria.Medical Directorate, Vienna General Hospital, Vienna, Austria.Centre for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria.Department of Ear, Nose and Throat Diseases, Medical University of Vienna, Vienna, Austria.Department of Anaesthesia, Critical Care and Pain Medicine, Medical University of Vienna, Vienna, Austria.Division of Clinical Virology, Medical University of Vienna, Vienna, Austria.Department of Hospital Epidemiology and Infection Control, Medical University of Vienna, Vienna, Austria.Department of Hospital Epidemiology and Infection Control, Medical University of Vienna, Vienna, Austria.Department of Hospital Epidemiology and Infection Control, Medical University of Vienna, Vienna, Austria.Department of Urology, Medical University of Vienna, Vienna, Austria.

Pub Type(s)

Journal Article
Observational Study

Language

eng

PubMed ID

34915073

Citation

Brunner-Ziegler, Sophie, et al. "Postvaccination Infections Among Staff of a Tertiary Care Hospital After Vaccination With Severe Acute Respiratory Syndrome Coronavirus 2 Vector and mRNA-based Vaccines." Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, vol. 28, no. 4, 2022, pp. 596-601.
Brunner-Ziegler S, Spath T, Kornek G, et al. Postvaccination infections among staff of a tertiary care hospital after vaccination with severe acute respiratory syndrome coronavirus 2 vector and mRNA-based vaccines. Clin Microbiol Infect. 2022;28(4):596-601.
Brunner-Ziegler, S., Spath, T., Kornek, G., König, F., Parschalk, B., Schnetzinger, M., Straβl, R. P., Savic, R., Foit, A., Resch, H., & Thalhammer, F. (2022). Postvaccination infections among staff of a tertiary care hospital after vaccination with severe acute respiratory syndrome coronavirus 2 vector and mRNA-based vaccines. Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 28(4), 596-601. https://doi.org/10.1016/j.cmi.2021.11.023
Brunner-Ziegler S, et al. Postvaccination Infections Among Staff of a Tertiary Care Hospital After Vaccination With Severe Acute Respiratory Syndrome Coronavirus 2 Vector and mRNA-based Vaccines. Clin Microbiol Infect. 2022;28(4):596-601. PubMed PMID: 34915073.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Postvaccination infections among staff of a tertiary care hospital after vaccination with severe acute respiratory syndrome coronavirus 2 vector and mRNA-based vaccines. AU - Brunner-Ziegler,Sophie, AU - Spath,Tibor, AU - Kornek,Gabriela, AU - König,Franz, AU - Parschalk,Bernhard, AU - Schnetzinger,Maximilian, AU - Straβl,Robert Paul, AU - Savic,Rebeka, AU - Foit,Andrea, AU - Resch,Helene, AU - Thalhammer,Florian, Y1 - 2021/12/13/ PY - 2021/09/04/received PY - 2021/11/16/revised PY - 2021/11/25/accepted PY - 2021/12/17/pubmed PY - 2022/4/6/medline PY - 2021/12/16/entrez KW - Breakthrough infection KW - Hospital employees KW - Postvaccination infection KW - Severe acute respiratory syndrome coronavirus 2 KW - Vector-based vaccine KW - mRNA-based vaccine SP - 596 EP - 601 JF - Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases JO - Clin Microbiol Infect VL - 28 IS - 4 N2 - OBJECTIVES: The identification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen or RNA in respiratory specimens ≥14 days after administration of all recommended doses of authorized coronavirus disease 2019 (COVID-19) vaccines is defined as breakthrough infection. In the present investigation, mRNA and vector-based SARS-CoV-2 vaccines were analysed with respect to postvaccination infections in vaccinated hospital employees. METHODS: A total of 8553 staff members were vaccinated with BNT162b2 (47%) or ChAdOx1-S (53%) between January and May 2021. In a retrospective observational cohort study, incidence of SARS-CoV-2 postvaccination infections was analysed in relation to demographic data, viral load, virus variants, vaccine brand and vaccination status at time of positive PCR test (fully vaccinated: ≥14 days since second dose; partially vaccinated: >21 days since first, but <14 days after second dose; insufficiently vaccinated: <22 days since first dose). RESULTS: Within the follow-up period, ending on 31 July 2021, person-time at risk-adjusted monthly rates for SARS-CoV-2 postvaccination infections were 0.18% (BNT162b2) and 0.57% (ChAdOx1-S) for insufficiently vaccinated, 0.34% (BNT162b2) and 0.32% (ChAdOx1-S) for partially vaccinated and 0.06% (BNT162b2) and 0.04% (ChAdOx1-S) for fully vaccinated participants. The two vaccine types did not differ with respect to hazard ratios for any of the respective postvaccination infection types. No cases of COVID-19-related hospitalizations or deaths were reported. Genotyping of positive PCR specimens revealed 42 variants of concern: B.1.1.7 (Alpha variant; n = 34); B.1.351 (Beta variant; n = 2), B.1.617.2 (Delta variant; n = 6). CONCLUSIONS: BNT162b2 and ChAdOx1-S are both effective in preventing breakthrough infections; however, it seems important, that all recommended vaccine doses are administered. SN - 1469-0691 UR - https://www.unboundmedicine.com/medline/citation/34915073/Postvaccination_infections_among_staff_of_a_tertiary_care_hospital_after_vaccination_with_severe_acute_respiratory_syndrome_coronavirus_2_vector_and_mRNA_based_vaccines_ DB - PRIME DP - Unbound Medicine ER -